PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419218
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1419218
Global acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 11.3% in the forecast period of 2024 to 2031. The new market report contains data for the historic year 2022, the base year of calculation is 2022, and the forecast period is 2024 to 2031.
Global Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments, and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), MONOCYTIC (M5), Erythroleukemia (M6) and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, 65, and Above), Gender (Male and Female) End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest Of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.
Driver
Increasing diagnostic products for leukemia cancer
Restraint
Late diagnosis and Poor prognosis of leukemia
Opportunity
Initiatives by government and other authorities for life sciences and funding